Form 4: Enliven Therapeutics Director Exercises Stock Options

Enliven Therapeutics Director Lori Anne Kunkel exercised 15,958 stock options at $1.12 per share, increasing her direct common stock holdings.

Summary

• Lori Anne Kunkel, a Director at Enliven Therapeutics, Inc. (ELVN), exercised 15,958 stock options on December 17, 2025.
• The exercise price for these options was $1.12 per share.
• Following the transaction, Kunkel directly holds 30,712 shares of common stock.
• Additionally, 31,172 shares are indirectly held by the Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE.
• After the exercise, Kunkel retains 3,741 stock options.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The exercise of stock options by a director is generally viewed as a neutral to slightly positive event, indicating continued insider ownership and commitment, rather than a divestment. It's a routine compensation-related transaction.

Positives

• Director Lori Anne Kunkel increased her direct beneficial ownership of Enliven Therapeutics common stock by 15,958 shares through the exercise of stock options.
• The exercise of options indicates a continued commitment to the company by a director.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the details of the option exercise.

Industry Context

This is a routine insider transaction, common in the biotechnology or pharmaceutical industry for directors and executives to exercise vested stock options as part of their compensation structure. It reflects a director's ongoing stake in the company.

Related Party Transactions

• 31,172 shares of common stock are indirectly held by the Lori Kunkel Revocable Trust DTD 11/08/2018 Lori A Kunkel TTEE, which is a related party to Director Lori Anne Kunkel.

Stakeholder Impact

• Shareholders may view the director's increased direct ownership as a positive signal of confidence in the company's future prospects.

Key Dates

Recommendation

This Form 4 reports a routine exercise of vested stock options by a director, which is a standard insider transaction and does not provide new fundamental information to alter an an investment thesis. While it shows continued insider ownership, it's not a strong buy or sell signal on its own.

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Transaction, Stock Option Exercise, Director Ownership, Lori Anne Kunkel, Beneficial Ownership, Rule 10b5-1 Plan